In the clinical diagnosis and treatment of tumors, off-label drug use occurs from time to time. An Guangyu, chief physician of the oncology department of Beijing Chaoyang Hospital, said that some elderly patients had difficulty obtaining enough tissue samples for pathological testing, and some doctors had to adopt experimental drug strategies.
On January 8, the General Office of the National Health Commission issued the "Guidelines for the Clinical Application of New Anti-tumor Drugs (2023 Edition)", which further standardizes the clinical application of tumors**.
An Guangyu said in an interview with the reporter of the people's ** health client, "The implementation of the new version of the principle is not only conducive to standardizing the diagnosis and treatment behavior of medical institutions, but also the dual care for the quality of life and economic burden of the majority of cancer patients." ”
The new version of the Principles provides clear guidance for such situations, emphasizing that regardless of the cause, caution should be exercised in the absence of a diagnosis of pathological tissue.
In addition, the Principles emphasize that the application of targeted drugs must be based on precise target detection results. An Guangyu said that with the increase in the types of targeted drugs, the phenomenon of blind trial without genetic testing has increased, which not only violates the principle of scientific drug use, but also greatly reduces the efficiency.
Regarding the possible impact on clinical practice after the promulgation of the new version of the Principles, An Guangyu said that the Principles will play a far-reaching role in six key aspects. From strengthening organizational diagnosis, strictly following the indications of targeted drugs, optimizing the pharmacoeconomic effect to rational drug use under special circumstances, etc., it will effectively standardize the diagnosis and treatment of malignant tumors at all levels and types of medical institutions.